1	Systematic analysis and prediction of genes associated with disorders							
2	on chromosome X							
3	Elsa Leitão, <sup>1</sup> Christopher Schröder, <sup>1</sup> Ilaria Parenti, <sup>1</sup> Carine Dalle, <sup>2</sup> Agnès Rastetter, <sup>2</sup> Theresa							
4	Kühnel, <sup>1</sup> Alma Kuechler, <sup>1</sup> Sabine Kaya, <sup>1</sup> Bénédicte Gérard, <sup>3</sup> Elise Schaefer, <sup>4</sup> Caroline Nava, <sup>2</sup>							
5	Nathalie Drouot, <sup>5</sup> Camille Engel, <sup>5</sup> , Juliette Piard, <sup>6,15</sup> Bénédicte Duban-Bedu, <sup>7</sup> Laurent Vil-							
6	lard, <sup>8,9</sup> Alexander P.A. Stegmann, <sup>10,11</sup> Els K. Vanhoutte, <sup>11</sup> Job A.J Verdonshot <sup>11,12</sup> , Frank J.							
7	Kaiser, <sup>1</sup> Frédéric Tran Mau-Them, <sup>13,14,15</sup> Marcello Scala, <sup>16,17</sup> Pasquale Striano, <sup>16,17</sup> Suzanna							
8	G.M. Frints, <sup>11,18</sup> Emanuela Argilli, <sup>19,20</sup> Elliott H. Sherr, <sup>19,20</sup> Fikret Elder, <sup>21</sup> Julien Buratti, <sup>21</sup> Bori							
9	Keren, <sup>21</sup> Cyril Mignot, <sup>2,21,22</sup> Delphine Héron, <sup>21,22</sup> Jean-Louis Mandel, <sup>3,5,23,24,25</sup> Jozef Gecz, <sup>26,27</sup>							
10	Vera M. Kalscheuer, <sup>28</sup> Bernhard Horsthemke, <sup>1</sup> Amélie Piton, <sup>3,5,24,24,25</sup> Christel Depienne <sup>1*</sup>							
11	<sup>1</sup> Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen,							
12	Germany							
13	<sup>2</sup> Institut du Cerveau et de la Moelle épinière (ICM), Sorbonne Université, UMR S 1127, In-							
14	serm U1127, CNRS UMR 7225, F-75013 Paris, France							
15	<sup>3</sup> Unité de Génétique Moléculaire, IGMA, Hôpitaux Universitaire de Strasbourg, Strasbourg,							
16	France							
17	<sup>4</sup> Service de Génétique Médicale, IGMA, Hôpitaux Universitaires de Strasbourg, Strasbourg,							
18	France							
19	<sup>5</sup> Institut de Génétique et de Biologie Moléculaire et Cellulaire, Illkirch 67400, France							
20	<sup>6</sup> Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France.							
21	<sup>7</sup> Centre de génétique chromosomique, Hôpital Saint-Vincent de Paul, Lille, France.							
22	<sup>8</sup> Aix-Marseille University, INSERM, MMG, UMR-S 1251, Faculté de médecine, Marseille,							
23	France NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.							

- <sup>9</sup> Département de Génétique Médicale, APHM, Hôpital d'Enfants de La Timone, Marseille,
- 25 France
- <sup>10</sup> Department of Human Genetics, Radboud University Medical Center, 6500 HB, Nijmegen,
- 27 the Netherlands
- <sup>28</sup> <sup>11</sup> Department of Clinical Genetics, Maastricht University Medical Center<sup>+</sup>, Maastricht, The
- 29 Netherlands
- 30 <sup>12</sup> Cardiovascular Research Institute (CARIM), Departments of Cardiology, Maastricht Univer-
- 31 sity Medical Center, the Netherlands
- 32 <sup>13</sup> Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, CHU Dijon
- 33 Bourgogne, Dijon, France
- <sup>34</sup> <sup>14</sup> Centre de Génétique, Centre de Référence Anomalies du Développement et Syndromes
- 35 Malformatifs, et Centre de Compétence Maladies Mitochondriales, FHU TRANSLAD, Hôpital
- 36 d'Enfants, CHU de Dijon, France
- <sup>15</sup> INSERM UMR1231, Equipe Génétique des Anomalies du Développement, Université de
- 38 Bourgogne, Dijon, France
- <sup>39</sup> <sup>16</sup> Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and
- 40 Child Health, University of Genoa, 16132 Genoa, Italy
- 41 <sup>17</sup> Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, 16147
- 42 Genoa, Italy
- 43 <sup>18</sup> Department of Genetics and Cell Biology, Faculty of Health Medicine Life Sciences, Maas-
- 44 tricht University Medical Center+, Maastricht University, Maastricht, The Netherlands
- 45 <sup>19</sup> Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
- <sup>20</sup> Institute of Human Genetics and Weill Institute for Neurosciences, University of California,
- 47 San Francisco, San Francisco, CA, USA

- 48 <sup>21</sup> UF de Génomique du Développement, Département de Génétique, Groupe Hospitalier Pi-
- 49 tié-Salpêtrière, APHP-Sorbonne Université, Paris, France.
- 50 <sup>22</sup> APHP, Sorbonne Université, Département de Génétique, Centre de Référence Déficiences
- 51 Intellectuelles de Causes Rares, Groupe Hospitalier Pitié-Salpêtrière and Hôpital Trousseau,
- 52 Paris, France
- <sup>23</sup> Centre National de la Recherche Scientifique, UMR7104, Illkirch 67400, France
- <sup>24</sup> Institut National de la Santé et de la Recherche Médicale, U964, Illkirch 67400, France
- 55 <sup>25</sup> Université de Strasbourg, Illkirch 67400, France
- <sup>26</sup> School of Biological Sciences, School of Medicine and Robinson Research Institute, The
- 57 University of Adelaide, Adelaide, 5005, SA, Australia
- 58 <sup>27</sup> South Australian Health and Medical Research Institute, The University of Adelaide, Ade-
- 59 laide, 5005, SA, Australia
- <sup>28</sup> Research Group Development and Disease, Max Planck Institute for Molecular Genetics,
- 61 Berlin, Germany.
- 62 \* Correspondence to: Christel Depienne (christel.depienne@uni-due.de)

# 63 Abstract

64 Disease gene discovery on chromosome (chr) X is challenging owing to its unique modes of 65 inheritance. We undertook a systematic analysis of human chrX genes. We observe a higher 66 proportion of disorder-associated genes and an enrichment of genes involved in cognition, 67 language, and seizures on chrX compared to autosomes. We analyze gene constraints, exon and promoter conservation, expression and paralogues, and report 127 genes sharing one or 68 69 more attributes with known chrX disorder genes. Using a neural network trained to distin-70 guish disease-associated from dispensable genes, we classify 235 genes, including 121 of the 71 127, as having high probability of being disease-associated. We provide evidence of an ex-72 cess of variants in predicted genes in existing databases. Finally, we report damaging variants 73 in CDK16 and TRPC5 in patients with intellectual disability or autism spectrum disorders. 74 This study predicts large-scale gene-disease associations that could be used for prioritization 75 of X-linked pathogenic variants.

# 76 Introduction

77 Sex in mammals is determined by a diverging pair of sex chromosomes (chr). Human fe-78 males have two copies of the 155-Mb chrX while males have a single X copy and a smaller 79 30-Mb chrY. Compensation of gene dosage in females is achieved through X chromosome 80 inactivation (XCI), a process leading to the epigenetic silencing of an entire chrX, apart from 81 two pseudoautosomal regions (PARs). This process happens during early embryonic develop-82 ment, is randomly and independently established in each cell, and stably maintained during 83 further cell divisions.<sup>1,2</sup> As a consequence, female individuals are cell mosaics, each cell expressing genes from either the maternal or paternal X copy.<sup>3</sup> A subset of genes, which can be 84 85 variable between individuals and tissues, escapes X inactivation and continues to be expressed from both X chromosomes.<sup>4</sup> 86

87

88 The last two decades have revolutionized concepts of X-linked inheritance, by depicting its unique but multiple forms.<sup>1,5</sup> The first and most widely described disorders (>100 89 90 genes) mainly affect hemizygous males and are transmitted through healthy or mildly symp-91 tomatic female carriers. Other modes of X-linked inheritance are mainly observed in disor-92 ders affecting the central nervous system. Variants in X-linked genes such as MECP2<sup>6</sup>,  $CDKL5^{7,8}$  and  $DDX3X^9$  preferentially affect heterozygous females. These variants usually oc-93 94 cur de novo, and hemizygous males are either not viable or survive only if variants are hypo-95 morphic or mosaic. Variants in other genes affect hemizygous males and heterozygous fe-96 males almost equally. The list of X-linked disorders first described as selectively affecting 97 males but turning out to also affect females is continually increasing and include  $IOSEC2^{10}$ , NEXMIF,<sup>11</sup> KDM5C,<sup>12</sup> HUWE1,<sup>13</sup> USP9X<sup>14</sup> and CLCN4.<sup>15</sup> Lastly, two X-linked disorders, 98 related to *PCDH19* and *EFNB1*, affect heterozygous females and postzygotic somatic mosaic 99 males (due to cellular interference), while hemizygous males are spared.<sup>16,17</sup> 100

101

102	Disease gene discovery on chrX is thus associated with greater challenges, including
103	male-female patient selection and variant interpretation biases, compared to autosomes. ChrX
104	is often omitted from genome-wide analyses in a research context due to the difficulty of
105	dealing with sex dichotomy in bioinformatics pipelines. Identifying novel gene-disease asso-
106	ciations on chromosome X requires dedicated studies of families with multiple affected
107	males <sup>18,19</sup> or multiple subjects with matching phenotypes. <sup>9</sup> The interpretation of X-linked var-
108	iants in sporadic cases and small families remains difficult in absence of extended segrega-
109	tion in the family, which is rarely available. Furthermore, the presence of damaging variants
110	at relatively high frequency in large databases (ExAC, gnomAD) led to question previously
111	established gene-disease associations. <sup>20</sup> The Deciphering Developmental Disorders (DDD)
112	consortium recently estimated that X-linked disorders overall affect males and females
113	equally and represent 6% of developmental disorders. <sup>21</sup> However, despite the remarkable size
114	of the cohort (11,044 affected individuals), this study failed to identify new X-linked disor-
115	der-associated genes.
116	

In this study, we first undertook a systematic analysis of all coding genes on human chromosome X and compared the proportion and characteristics of associated disorders to those on autosomes. In a second step, we investigated the relevance of multiple variables to predict gene-disorder associations. Lastly, we used these predictions to uncover new diseasegene associations supported by the literature as well as by patient data and functional studies.

# 122 **Results**

#### 123 Chromosome X is enriched in disorder genes and in genes relevant to brain function

- 124 Chromosome X comprises 829 protein coding genes annotated in HUGO Gene Nomenclature
- 125 Committee (HGNC), including 205 associated with at least one monogenic disorder (referred
- 126 to as 'disorder genes') in OMIM (Fig. 1a). We used the clinical synopsis to compare the pro-
- 127 portion of disorder genes and their associated clinical features on chrX (available for 202
- genes) and autosomes (Supplementary Methods, Fig. 1b). We observed a significant and spe-
- 129 cific enrichment in disorder genes on chrX (24% versus 12-22%,  $p=1.87\times10^{-3}$ ; OR=1.5; Fig.
- 130 1c-d and Supplementary Tables 1-4). Furthermore, genes on chrX were significantly more
- 131 frequently associated with neurological phenotypes than genes on autosomes (77% versus 55-

132 76%;  $p=7.01\times10^{-3}$ ; OR=2.0; Fig. 1e-f). More specifically, we observed that chrX is enriched

- in genes associated with intellectual disability (ID; 58% versus 27-45%;  $p=5.92\times10^{-11}$ ;
- 134 OR=2.9), seizures (46% versus 23-38%;  $p=1.12\times10^{-4}$ ; OR=2.1) and language impairment
- 135 (32% versus 11-24%;  $p=5.59\times10^{-3}$ ; OR=2.0; Fig. 1g-l), but not motor development, spastic-
- 136 ity, or ataxia (Fig. 1m-n; Extended Data Fig. 1a-b; Supplementary Table 5). The difference
- 137 remained significant when genes associated with provisional gene-phenotype relationships
- 138 (P), susceptibility to multifactorial disorders (M) or traits (T) (referred to as 'PMT' genes)
- 139 were included in the comparison (Extended Data Fig. 1c-d; Supplementary Tables 4 and 5).
- 140 In total, 84% of known disease genes on chrX are associated with ID, seizures or language
- 141 impairment and about 30% are associated with all three clinical outcomes (Fig. 10).

142

# 143 Confirmed disorder-associated genes share specific features

- 144 Despite chrX being enriched in disorder-associated genes, 598 genes (71%) are not yet re-
- 145 lated to any clinical phenotype (referred to as 'no-disorder genes'; Fig. 1a). We hypothesized
- 146 that disorder genes share specific common features that dispensable genes do not exhibit and

147	that could be used to predict genes that remain to be associated with human disorders. To test
148	this hypothesis, we retrieved annotations from different sources and/or calculated additional
149	metrics, including: 1) gnomAD gene constraint metrics: LOEUF (rank of intolerance to loss-
150	of-function (LoF) variants), misZ (intolerance to missense variants score) and synZ (intoler-
151	ance to synonymous variants score); 2) coding-sequence (CDS) length; 3) the degree of ex-
152	ons and promoter conservation across 100 species; 4) the promoter CpG density; <sup>22</sup> and 5)
153	gene expression data, conveyed as a tissue specificity measure (tau) and brain-related expres-
154	sion levels from GTEx and BrainSpan resources (Supplementary Table 1).
155	

156 We investigated whether the distribution of these variables differ between disorder 157 genes and no-disorder genes. As expected, disorder genes had lower LOEUF values and 158 higher misZ scores but similar synZ scores than no-disorder genes. We observed a significant 159 enrichment of disorder genes in the three lowest LOEUF deciles and in the two highest misZ 160 deciles, with the distributions of LOEUF and misZ metrics in the PMT group showing inter-161 mediate values between disorder and no-disorder genes (Fig. 2a-b). Disorder genes were enriched in the highest decile of exon conservation, promoter conservation scores and CDS 162 163 length distribution with an overall distribution that was variable in all groups (Fig. 2c; Ex-164 tended Data Fig. 2; Supplementary Table 6). Disorder genes tended to present higher pro-165 moter CpG density than no-disorder genes, although the difference was not significant. Re-166 markably, we observed that disorder genes are more broadly expressed (tau<0.6) and show 167 intermediary levels of gene expression in brain-tissues compared to no-disorder genes, for 168 which expression was more often restricted to a few tissues (tau>0.6) and are less expressed 169 in the brain (Extended Data Fig. 2).

171	We next investigated how the existence of close paralogues and the location in PARs
172	may influence their relationship to human disease. From the 18 PAR protein-coding genes,
173	only two (SHOX and CSF2RA) have been associated with a medical condition so far. We also
174	observed that disorder genes are significantly depleted in close paralogues compared to
175	PMT/no-disorder genes ( $p=3.1\times10^{-6}$ ; OR = 0.33; Extended Data Fig. 3a-d). This suggests that
176	highly similar paralogues might compensate pathogenic variants in corresponding X-linked
177	genes.

178

Previous comparisons suggest that LOEUF, misZ, and exon conservation scores, 179 180 which showed marked differences between the two subgroups, can best differentiate disorder 181 from no-disorder genes. We then focused on the deciles enriched in disorder genes to list the 182 genes in the no-disorder group exhibiting similar characteristics (Fig. 2d). More specifically, 183 we defined thresholds for LOEUF, misZ, and exon conservation scores as follows: LOEUF  $\leq$ 184 0.326 (L), misZ  $\ge 2.16$  (M), and/or exon-score  $\ge 0.9491$  (E). 149 of the 205 (73%) disorder 185 genes met one or more L, M or E (LME) criteria (Fig. 2e). Among the 205 disorder genes, 56 genes failing to meet any of the LOEUF/misZ criteria had a smaller CDS length ( $p=4.20\times10^{-10}$ 186 <sup>9</sup>), indicating that the performance of LOEUF and misZ in differentiating disorder from no-187 188 disorder genes depends on CDS length (Extended Data Fig. 3e). Exon conservation alone al-189 lowed retrieving eight disorder genes with small CDS for which LOEUF and misZ failed to 190 reach the thresholds (Extended Data Fig. 3e; Supplementary Table 1). When applying the 191 same thresholds to the 598 genes not associated with disease, 127 (21%) genes fulfilled at 192 least one condition and 35 fulfilled at least two criteria (Fig. 2e; Supplementary Table 1). 193 Half (n=13) of the PMT genes also met at least one criterion and seven at least two criteria 194 (Fig. 2e). Altogether, 140 genes shared at least one of the LME criteria with known disorder 195 genes.

196

#### 197 Prediction of novel disorder-associated genes on chrX

198 The threshold approach was limited by the number of variables that could be taken into ac-199 count to differentiate disorder from no-disorder genes. We then used machine learning to pre-200 dict remaining disorder genes in a more systematic and unbiased fashion. As most X-linked 201 disorders are associated with neurological features, we trained a neural network (NN) to dis-202 tinguish two classes of genes: 1) known disorder genes associated with neurological features on all chromosomes and 2) dispensable genes as defined by Karczewski et al. (2020)<sup>23</sup> (Sup-203 204 plementary Methods; Extended Data Fig. 4; Extended Data Fig. 5a-b). We used additional 205 variables including expression data stratified according to sex and data on paralogues (Sup-206 plementary Tables 7 and 8). Although using data on all chromosomes, the neural network 207 performed remarkably better for genes on chrX, predicting 191 (93%) of the 205 known dis-208 order genes on this chromosome using FDR < 0.05 (Extended Data Fig. 5c-f). 145 of the pre-209 dicted genes met the LME thresholds (Fig. 2f). The NN confirmed 16 of the 26 PMT genes as 210 disease-associated, 13 of which also met LME criteria (Fig. 2f, Fig. 3a-b). Focusing on the 598 no-disorder genes on chrX, the NN predicted 235 as disease-associated (FDR < 0.05; 211 212 Supplementary Table 9; Extended data Fig. 5a). 121 genes (51%) also met at least one of the 213 LME criteria (Fig. 2f), with four meeting all three, 30 two and 87 genes one criterion (Fig. 214 3c). The 114 remaining genes predicted by the NN did not meet any LME criteria (Fig. 3d), 215 whereas only six meeting LME criteria were not predicted by the NN (Fig. 3e). Altogether, 216 these results suggest that the NN is a valid approach to predict genes remaining to be associ-217 ated with disease with high accuracy.

218

## 219 Validation of putative novel disorder genes

220 To provide additional evidence supporting our predictions, we searched for evidence from 221 databases or the literature that variants in the 235 NN-predicted genes could indeed result in 222 new X-linked disorders. We first used HGMD and DECIPHER to retrieve the number of sin-223 gle nucleotide variants and indels of unknown significance reported in each gene and com-224 pared the number of variants in predicted versus non-predicted gene categories (Supplemen-225 tary Table 9). This analysis revealed that the 235 NN-predicted disorder genes are enriched in point variants compared to non-predicted genes ( $p=5.3\times10^{-6}$ ; OR=2.2), suggesting that this 226 227 excess is due to pathogenic variants. NN-predicted genes meeting at least one LME criterion 228 had more point variants than predicted genes that do not meet any LME criterion (Fig. 4a-b; 229 Extended Data Fig. 6).

230

231 Second, we used the SysID and Gene2Phenotype (G2P) developmental disorders da-232 tabases to compare the overlap of predicted and non-predicted genes (Fig. 4c). Nine of the 16 233 NN-predicted PMT genes were in SysID (Fig. 3a-b). Three genes (PTCHD1, NLGN3, and 234 KIF4A), indicated as confirmed SysID genes, were also in G2P. PTCHD1 and NLGN3 are as-235 sociated with susceptibility to autism in OMIM, but both were recently confirmed to cause a monogenic ID disorder frequently associated with autism.<sup>24-26</sup> A splice site variant in KIF4A 236 was identified in a family with four affected males,<sup>27</sup> and this finding was recently strength-237 ened by the identification of additional de novo or inherited variants causing a range of differ-238 ent phenotypic manifestations.<sup>28,29</sup> Focusing on no-disorder genes, 21 (9%) of the NN-pre-239 240 dicted genes and 14 (4%) of the non-predicted genes were in SysID (Fig. 3c-d). Five pre-241 dicted genes (CSTF2, FGF13, PLXNA3, OTUD5 and STEEP1) were confirmed SysID genes. 242 In addition, six genes (ARHGEF6, CDK16, FGF13, GSPT2, MMGT1 and ZDHHC15) had 243 entries in G2P. Pathogenic variants in OTUD5 and FGF13 respectively cause a severe neuro-

244	developmental disorder with multiple congenital anomalies and early lethality, <sup>30,31</sup> and devel-
245	opmental and epileptic encephalopathy, <sup>32</sup> both described in 2021. <i>PLXNA3</i> have been associ-
246	ated with ID and autism spectrum disorders (ASD), <sup>33</sup> or hypogonadotropic hypogonadism. <sup>34</sup>
247	Additional evidence from the literature not yet reflected in OMIM or any other database in-
248	clude possibly pathogenic variants described in one or a few families in ZMYM3, <sup>35</sup> GLRA2, <sup>36</sup>
249	and GPKOW. <sup>37</sup> Although some of these genes now have an OMIM disorder entry, their asso-
250	ciation with a monogenic disorder was not known at the beginning of our study.

251

252 Third, we retrieved the number of *de novo* predicted damaging (truncating or CADD $\geq$ 25) variants identified in these genes from the Martin et al.<sup>21</sup> and Kaplanis et al.<sup>38</sup> 253 254 studies. In parallel, we examined exome data from two additional cohorts of patients with de-255 velopmental disorders, containing mainly patients with intellectual disability (6500 from 256 2346 families [Paris-APHP cohort] and 1399 individuals from 463 families [UCSF cohort] 257 and extracted predicted damaging variants in NN-predicted genes meeting at least one LME 258 criterion (Supplementary Table 10). This led us to select 13 genes containing de novo damag-259 ing variants and additional predicted damaging variants identified in independent cohorts 260 (Fig. 5). Interestingly, 19 out the 55 missense variants reported in these 13 genes are localized 261 in known functional protein domains (Fig. 5; Supplementary Table 11). Among those genes, SMARCA1 has been associated with syndromic intellectual disability and Coffin-Siris-like 262 features by the Clinical Genome Resource (ClinGen) with moderate evidence.<sup>39</sup> 263 264 CDK16 and TRPC5 are novel genes associated with intellectual disability 265 266 Lastly, we focused on CDK16 and TRPC5, both predicted by the NN and threshold approaches but for which genetic evidence was limited (Fig. 6a-b). CDK16 encodes a protein 267

268 kinase involved in neurite outgrowth, vesicle trafficking and cell proliferation.<sup>40</sup> A deletion of

269	two nucleotides leading to a frameshift (NM_006201.5: c.976_977del, p.(Trp326Valfs*5))						
270	segregating in four males with ID, ASD, absence seizures and mild spasticity was reported in						
271	this gene by Hu et al. <sup>18</sup> Using exome sequencing, we identified a nonsense variant						
272	(c.961G>T, p.(Glu321*)) in an adult patient with ID and spasticity. A missense variant						
273	(c.1039G>T, p.(Gly347Cys)) affecting a highly conserved amino acid of the kinase domain						
274	(CADD PHRED score: 32) was identified by genome sequencing in a male patient with ID,						
275	ASD and epilepsy, whose family history was compatible with X-linked inheritance (Fig. 6a						
276	and c; Supplementary Table 12). In addition, a nonsense variant (c.46C>T, p.(Arg16*)) was						
277	recently reported in a patient with ASD by Satterstrom et al. <sup>41</sup>						
278							
279	TRPC5 encodes the short transient receptor potential channel 5, a channel permeable						
280	to calcium predominantly expressed in the brain. <sup>42</sup> We identified a missense variant in this						
281	gene (NM_012471.2:c.523C>T, p.(Arg175Cys), CADD PHRED score: 29.8) in three male						

siblings with ID and ASD. The variant was maternally inherited but absent from the maternal

283 grandparents (Fig. 6b and d; Supplementary Table 12). We investigated the functional impact

284 of the p.(Arg175Cys) variant on the TRPC5 channel using whole-cell patch-clamp. Immedi-

ately after break-in, HEK293 cells expressing mutant TRPC5 exhibited an increase in imme-

286 diate current recorded compared with cell expressing wild-type TRPC5 (p= 0.009 for out-

ward current at -80mV and p=0.002 for inward current at -80mV; Fig.6 e-g), suggesting a

288 constitutively active current. A nonsense variant (c.965G>A, p.(Trp322\*)) was identified by

290 coding exon of *TRPC5*, encoding conserved ankyrin repeats, was previously reported in a pa-

exome sequencing in a patient with high-functioning ASD. An intragenic deletion of the first

289

tient with ASD who had a family history compatible with X-linked inheritance.<sup>43</sup> In addition,

three *de novo* variants in *TRPC5* (p.(Pro667Thr), p.(Arg71Gln), p.(Trp225\*)) had been iden-

tified in patients with intellectual disability and/or autism disorders in the literature.<sup>21,44,45</sup>

294

Altogether, these results strongly suggest that pathogenic variants altering the functions of *CDK16* and *TRPC5* lead to novel X-linked disorders featuring ID and ASD.

#### 298 Discussion

299 Male and female individuals tolerate pathogenic variants on chrX in different manners. Vari-300 ants in X-linked genes have to be interpreted taking this complexity into account. We aimed 301 at providing an inventory of disorder genes on chrX and predict genes that remain to be asso-302 ciated with human disease, assuming that they share similar characteristics. We first used a 303 threshold approach to list genes similarly constrained during evolution, which are the most 304 likely to lead to disease when altered by genetic variants. This revealed 127 novel genes shar-305 ing at least one constraint metric with known disorder genes and 35 sharing at least two. To 306 avoid bias and limitations linked to this approach, we used a hypothesis-free neural network 307 to differentiate genes associated with brain disorders from genes where damaging variants are 308 tolerated (dispensable genes). The NN predicted 235 genes as putative disorder genes, includ-309 ing most of the genes uncovered by the threshold approach.

310

Our predictions are supported by a higher number of point variants reported in DECI-PHER and HGMD in predicted versus non-predicted genes, which strengthens the probability that variants reported contribute to the patients' phenotypes and prompts the prioritization of these genes in further genetic analyses. We notably highlight 13 genes in which several possibly pathogenic variants in functional domains have been identified in patients, likely constituting novel neurodevelopmental disorder genes. Furthermore, a subset of predicted genes

(e.g. *OTUD5*, *FGF13*, *GLRA2* and *GPKOW*) have already been associated with human diseases, although these associations had no OMIM Gene-Phenotype Relationship entries when
we started our study. Furthermore, we provide additional evidence that variants in two predicted genes, *CDK16* and *TRPC5*, likely cause novel X-linked disorders by gathering genetic
and clinical data of unrelated families with damaging variants in these genes.

322

323 Altogether, our gene-focused approach therefore suggests that less than half of genes 324 associated with human pathology on chrX are known so far and many more remain to be 325 characterized clinically, which challenges the recent estimation that X-chromosome has been saturated for disease genes.<sup>21</sup> The differences in conclusions may come from recruitment bias 326 327 in the DDD study, with inclusion of families with X-linked inheritance in more specific stud-328 ies, as well as from the patient-driven approach itself, which only allows detecting what is 329 statistically significant in a sample, no matter how large this sample is. It is indeed possible or 330 even likely that phenotypes associated with genes we predict are ultra-rare, lethal in utero, 331 difficult to recognize or assess clinically, or associated with atypical modes of X-linked in-332 heritance, making their identification difficult using classical genetic approaches.

333

Focusing on known genes associated with monogenic conditions in the first part of this study, we observed a higher proportion of genes associated with disorders on chrX compared to autosomes. This finding suggests that family-driven approaches have been more efficient in identifying disorder-associated genes on this chromosome. Nevertheless, considering disease-causing genes independently of their proportion, we also observed an enrichment of genes associated with specific neurological features such as ID, seizures, and language delay on chrX. The specific association of X-linked genes with cognitive functions has largely been

conveyed in the literature but, to our knowledge, this study is the first demonstrating the statistical significance of this finding using a systematic unbiased analysis. The reason why so
many genes important for cognition and language are on a sex chromosome is fascinating but
remains so far mysterious.<sup>46</sup>

345

346 Our study also indicates that disorder genes on chrX are depleted in highly similar pa-347 ralogues (>95% identity) compared to PMT/no-disorder genes, a finding that remained significant for predicted genes compared to non-predicted ones ( $p<2.2\times10^{-16}$ ; OR= 0.22). The 348 349 consequence of the existence of paralogues for disorders is probably different depending on 350 the expression of these paralogues and the ability of the gene product to compensate the func-351 tion of the original genes. Interestingly, 20% of genes on chrX have paralogues with >95% 352 identity. This list includes copies or retrocopies on autosomes, a functional redundancy that 353 has been attributed at least partly to the transcriptional silencing of chromosome X during 354 spermatogenesis.<sup>47,48</sup> Although many gene copies or retrocopies are specifically expressed in 355 male germ cells, others are still broadly expressed and could therefore buffer genetic variants in the X-linked paralogous genes, as shown for UPF3B and UPF3A.<sup>49</sup> The existence of pa-356 357 ralogues is also linked in some ways to the location in PAR regions and escape to XCI. In-358 deed, genes in PAR have paralogues on chrY and escape inactivation.<sup>50</sup> Accordingly, 35 of 359 the 231 predicted genes outside PAR also show some degree of escape from X inactivation 360 (Supplementary Table 1). Interestingly, genes escaping XCI outside PAR, including *IOSEC2* and *KDM5C*, may lead to disorders manifesting in both sexes.<sup>10,12</sup> Our study indicates that 361 362 genes in PAR and genes with close paralogues are less likely to be associated with a disorder, 363 suggesting that paralogues can compensate pathogenic variants in some X-linked genes and 364 raising the possibility of digenism or oligogenism in genes with redundant functions.

365

366 Our study focused on coding genes and did not include genes encoding long non-cod-367 ing RNA (lncRNA) or other RNA classes, which are however very abundant on chrX. Only a 368 few non-coding genes have been associated with disease so far and we believe that con-369 straints and pathological mechanisms applying to non-coding genes are likely different from 370 those of coding genes. In this respect, our study only predicts genes associated with disorders 371 when affected by usual mutation types. Therefore, our findings do not exclude that non-pre-372 dicted genes could lead to disease when associated with unusual mechanisms, such as gain of 373 a new function, dominant-negative impact on another gene, and ectopic expression of a gene 374 in the wrong tissue or at an abnormal time during development.

375

In conclusion, our study provides new insights into the complexity of X-linked disorders and indicates that alternative approaches not initially based on patient cohorts are effective to reveal gene-disease associations. We provide a list of genes that are likely to be associated with human disorders. Further studies are required to delineate these disorders clinically and determine whether males and/or females harboring variants in these genes are affected.

#### 382 References

383 384	1.	Balaton, B.P., Dixon-McDougall, T., Peeters, S.B. & Brown, C.J. The eXceptional nature of the X chromosome. <i>Hum Mol Genet</i> <b>27</b> , R242-R249 (2018).
385 386	2.	Galupa, R. & Heard, E. X-Chromosome Inactivation: A Crossroads Between Chromosome Architecture and Gene Regulation. <i>Annu Rev Genet</i> <b>52</b> , 535-566 (2018).
387 388	3.	Orstavik, K.H. X chromosome inactivation in clinical practice. <i>Hum Genet</i> <b>126</b> , 363-73 (2009).
389 390	4.	Tukiainen, T. <i>et al.</i> Landscape of X chromosome inactivation across human tissues. <i>Nature</i> <b>550</b> , 244-248 (2017).
391 392	5.	Migeon, B.R. X-linked diseases: susceptible females. <i>Genet Med</i> <b>22</b> , 1156-1174 (2020).
393 394	6.	Kaur, S. & Christodoulou, J. MECP2 Disorders. in <i>GeneReviews((R))</i> (eds. Adam, M.P. <i>et al.</i> ) (Seattle (WA), 1993).
395 396 397	7.	Weaving, L.S. <i>et al.</i> Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. <i>Am J Hum Genet</i> <b>75</b> , 1079-93 (2004).
398 399 400	8.	Tao, J. <i>et al.</i> Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. <i>Am J Hum Genet</i> <b>75</b> , 1149-54 (2004).
401 402 403	9.	Snijders Blok, L. <i>et al.</i> Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling. <i>Am J Hum</i> <i>Genet</i> <b>97</b> , 343-52 (2015).
404 405	10.	Mignot, C. <i>et al.</i> IQSEC2-related encephalopathy in males and females: a comparative study including 37 novel patients. <i>Genet Med</i> <b>21</b> , 837-849 (2019).
406 407	11.	Stamberger, H. <i>et al.</i> NEXMIF encephalopathy: an X-linked disorder with male and female phenotypic patterns. <i>Genet Med</i> <b>23</b> , 363-373 (2021).
408 409 410	12.	Carmignac, V. <i>et al.</i> Further delineation of the female phenotype with KDM5C disease causing variants: 19 new individuals and review of the literature. <i>Clin Genet</i> <b>98</b> , 43-55 (2020).
411 412	13.	Moortgat, S. <i>et al.</i> HUWE1 variants cause dominant X-linked intellectual disability: a clinical study of 21 patients. <i>Eur J Hum Genet</i> <b>26</b> , 64-74 (2018).
413 414	14.	Jolly, L.A. <i>et al.</i> Missense variant contribution to USP9X-female syndrome. <i>NPJ Genom Med</i> <b>5</b> , 53 (2020).
415 416 417	15.	Palmer, E.E. <i>et al.</i> De novo and inherited mutations in the X-linked gene CLCN4 are associated with syndromic intellectual disability and behavior and seizure disorders in males and females. <i>Mol Psychiatry</i> <b>23</b> , 222-230 (2018).
418 419	16.	Depienne, C. & LeGuern, E. PCDH19-related infantile epileptic encephalopathy: an unusual X-linked inheritance disorder. <i>Hum Mutat</i> <b>33</b> , 627-34 (2012).
420 421 422	17.	Wieland, I. <i>et al.</i> Dissecting the molecular mechanisms in craniofrontonasal syndrome: differential mRNA expression of mutant EFNB1 and the cellular mosaic. <i>Eur J Hum Genet</i> <b>16</b> , 184-91 (2008).
423 424	18.	Hu, H. <i>et al.</i> X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. <i>Mol Psychiatry</i> <b>21</b> , 133-48 (2016).

425 426	19.	Tarpey, P.S. <i>et al.</i> A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. <i>Nat Genet</i> <b>41</b> , 535-43 (2009).
427 428 429	20.	Piton, A., Redin, C. & Mandel, J.L. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. <i>Am J Hum Genet</i> <b>93</b> , 368-83 (2013).
430 431	21.	Martin, H.C. <i>et al.</i> The contribution of X-linked coding variation to severe developmental disorders. <i>Nat Commun</i> <b>12</b> , 627 (2021).
432 433 434	22.	Boukas, L., Bjornsson, H.T. & Hansen, K.D. Promoter CpG Density Predicts Downstream Gene Loss-of-Function Intolerance. <i>Am J Hum Genet</i> <b>107</b> , 487-498 (2020).
435 436	23.	Karczewski, K.J. <i>et al.</i> The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nature</i> <b>581</b> , 434-443 (2020).
437 438	24.	Quartier, A. <i>et al.</i> Novel mutations in NLGN3 causing autism spectrum disorder and cognitive impairment. <i>Hum Mutat</i> <b>40</b> , 2021-2032 (2019).
439 440 441	25.	Chaudhry, A. <i>et al.</i> Phenotypic spectrum associated with PTCHD1 deletions and truncating mutations includes intellectual disability and autism spectrum disorder. <i>Clin Genet</i> <b>88</b> , 224-33 (2015).
442 443 444	26.	Halewa, J. <i>et al.</i> Novel missense mutations in PTCHD1 alter its plasma membrane subcellular localization and cause intellectual disability and autism spectrum disorder. <i>Hum Mutat</i> <b>42</b> , 848-861 (2021).
445 446 447	27.	Willemsen, M.H. <i>et al.</i> Involvement of the kinesin family members KIF4A and KIF5C in intellectual disability and synaptic function. <i>J Med Genet</i> <b>51</b> , 487-94 (2014).
448 449	28.	Kalantari, S. <i>et al.</i> Expanding the KIF4A-associated phenotype. <i>Am J Med Genet A</i> <b>185</b> , 3728-3739 (2021).
450 451 452	29.	Gowans, L.J.J. <i>et al.</i> Missense Pathogenic variants in KIF4A Affect Dental Morphogenesis Resulting in X-linked Taurodontism, Microdontia and Dens- Invaginatus. <i>Front Genet</i> <b>10</b> , 800 (2019).
453 454	30.	Beck, D.B. <i>et al.</i> Linkage-specific deubiquitylation by OTUD5 defines an embryonic pathway intolerant to genomic variation. <i>Sci Adv</i> <b>7</b> (2021).
455 456 457	31.	Tripolszki, K. <i>et al.</i> An X-linked syndrome with severe neurodevelopmental delay, hydrocephalus, and early lethality caused by a missense variation in the OTUD5 gene. <i>Clin Genet</i> <b>99</b> , 303-308 (2021).
458 459 460	32.	Fry, A.E. <i>et al.</i> Missense variants in the N-terminal domain of the A isoform of FHF2/FGF13 cause an X-linked developmental and epileptic encephalopathy. <i>Am J Hum Genet</i> <b>108</b> , 176-185 (2021).
461 462	33.	Steele, J.L. <i>et al.</i> Semaphorin-Plexin Signaling: From Axonal Guidance to a New X- Linked Intellectual Disability Syndrome. <i>Pediatr Neurol</i> <b>126</b> , 65-73 (2022).
463 464 465	34.	Kotan, L.D. <i>et al.</i> Loss-of-function variants in SEMA3F and PLXNA3 encoding semaphorin-3F and its receptor plexin-A3 respectively cause idiopathic hypogonadotropic hypogonadism. <i>Genet Med</i> <b>23</b> , 1008-1016 (2021).
466 467 468	35.	Philips, A.K. <i>et al.</i> X-exome sequencing in Finnish families with intellectual disabilityfour novel mutations and two novel syndromic phenotypes. <i>Orphanet J Rare Dis</i> <b>9</b> , 49 (2014).

469 470	36.	Pilorge, M. <i>et al.</i> Genetic and functional analyses demonstrate a role for abnormal glycinergic signaling in autism. <i>Mol Psychiatry</i> <b>21</b> , 936-45 (2016).
471 472 473	37.	Carroll, R. <i>et al.</i> Variant in the X-chromosome spliceosomal gene GPKOW causes male-lethal microcephaly with intrauterine growth restriction. <i>Eur J Hum Genet</i> <b>25</b> , 1078-1082 (2017).
474 475	38.	Kaplanis, J. <i>et al.</i> Evidence for 28 genetic disorders discovered by combining healthcare and research data. <i>Nature</i> <b>586</b> , 757-762 (2020).
476 477 478	39.	Strande, N.T. <i>et al.</i> Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. <i>Am J</i> <i>Hum Genet</i> <b>100</b> , 895-906 (2017).
479 480	40.	Gillani, S.Q. <i>et al.</i> Regulation of PCTAIRE1 protein stability by AKT1, LKB1 and BRCA1. <i>Cell Signal</i> <b>85</b> , 110032 (2021).
481 482 483	41.	Satterstrom, F.K. <i>et al.</i> Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. <i>Cell</i> <b>180</b> , 568-584 e23 (2020).
484 485	42.	Beck, A. <i>et al.</i> Conserved gating elements in TRPC4 and TRPC5 channels. <i>J Biol Chem</i> <b>288</b> , 19471-83 (2013).
486 487 488	43.	Mignon-Ravix, C. <i>et al.</i> Intragenic rearrangements in X-linked intellectual deficiency: results of a-CGH in a series of 54 patients and identification of TRPC5 and KLHL15 as potential XLID genes. <i>Am J Med Genet A</i> <b>164A</b> , 1991-7 (2014).
489 490 491	44.	Kosmicki, J.A. <i>et al.</i> Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. <i>Nat Genet</i> <b>49</b> , 504-510 (2017).
492 493	45.	de Ligt, J. <i>et al.</i> Diagnostic exome sequencing in persons with severe intellectual disability. <i>N Engl J Med</i> <b>367</b> , 1921-9 (2012).
494 495 496	46.	Graves, J.A., Gecz, J. & Hameister, H. Evolution of the human Xa smart and sexy chromosome that controls speciation and development. <i>Cytogenet Genome Res</i> <b>99</b> , 141-5 (2002).
497 498	47.	Potrzebowski, L. <i>et al.</i> Chromosomal gene movements reflect the recent origin and biology of therian sex chromosomes. <i>PLoS Biol</i> <b>6</b> , e80 (2008).
499 500 501	48.	Marques, A.C., Dupanloup, I., Vinckenbosch, N., Reymond, A. & Kaessmann, H. Emergence of young human genes after a burst of retroposition in primates. <i>PLoS Biol</i> <b>3</b> , e357 (2005).
502 503 504	49.	Nguyen, L.S. <i>et al.</i> Transcriptome profiling of UPF3B/NMD-deficient lymphoblastoid cells from patients with various forms of intellectual disability. <i>Mol Psychiatry</i> <b>17</b> , 1103-15 (2012).
505	50.	Raudsepp, T. & Chowdhary, B.P. The Eutherian Pseudoautosomal Region. Cytogenet

506 Genome Res 147, 81-94 (2015).

# 507 Supplementary Methods

#### 508 **Protein-coding genes**

Annotations of genes in all chromosomes were downloaded from the HUGO Gene Nomenclature Committee (HGNC) database in November 2020 focusing on protein-coding genes
with approved status and present in the reference assembly.<sup>51</sup> *MED14OS* was excluded from
chrX-focused analysis due to its encoded protein being curated in Uniprot as "Product of a
dubious CDS prediction". Information concerning genes in PARs was also retrieved from
HGNC.

#### 515 Gene-phenotype relationships

516 Gene associations with disorders and/or traits were retrieved from data files provided by 517 Online Mendelian Inheritance in Man (OMIM). Information concerning the Clinical Synopsis 518 of phenotypes was obtained through OMIM Search. OMIM morbid genes were annotated for 519 1) the availability of Clinical Synopsis data for any of the associated phenotypes, 2) the exist-520 ence of Clinical Synopsis neurologic features in any of the associated phenotypes and 3) the 521 presence of terms related to intellectual disability, seizures, impaired language development, 522 impaired motor development, spasticity and ataxia among the Clinical Synopsis neurologic 523 features. For the latter and due to the free-text nature of the Clinical Synopsis data, synonymous terms and sentences of the above-mentioned clinical features were used and their com-524 525 plete lists are shown in Supplementary Table 2. Genes were divided into three groups based 526 on the existence and type of their gene-phenotype relationships: 1) "confirmed" when associ-527 ated with at least one confirmed monogenic disorder; 2) "PMT" for genes either with provi-528 sional gene-phenotype relationship (P), or associated with susceptibility factors to multifacto-

rial disorders (M) or with traits (T), which are labelled in the OMIM Gene Map with a question mark, braces or brackets, respectively; 3) "no disorder" for genes showing no phenotype associations. For each chromosome, we calculated the fraction of protein-coding genes that are CS-genes and the fraction of CS-genes that contain non-specific or specific neurologic features in the associated Clinical Synopsis data.

## 534 Gene intolerance to variation

- 535 Metrics related to intolerance of chrX genes to genetic variation (loss-of-function (LoF), mis536 sense and synonymous) were retrieved from the Genome Aggregation Database (gnomAD)
- 537 v2.1.1 <sup>23</sup> after conversion of gene identifiers to HGNC approved symbols. For genes with
- 538 available data for multiple transcripts, the metrics of the one with lowest LoF observed/ex-
- 539 pected upper bound fraction (LOEUF) were kept.

### 540 Gene expression data

Median gene-level transcripts per million (TPM) for 54 tissues from the v8 release were downloaded from the GTEx portal <sup>52</sup>. The robust tissue specificity measure tau <sup>53,54</sup> was calculated for chrX genes as previously described, aggregating the median expression of each gene for the different brain regions into two values: i) the median of the values for the two cerebellar regions and ii) the median of the values for the other brain tissues.<sup>22</sup> Genes with tau below 0.6 are broadly expressed, while tau higher than 0.6 indicates genes expressed in a restricted number of tissues.

548

Additional expression data was downloaded from the BrainSpan Atlas of the Developing Human Brain.<sup>55</sup> The Developmental Transcriptome Dataset contains gene summarized RPKM (Reads Per Kilobase of transcript, per Million mapped reads) normalized expression

values generated across 13 developmental stages in 8-16 brain structures from a total of 42
individuals of both sexes. After conversion of RPKM to TPM and gene identifiers to HGNC
approved symbols, we restricted to genes on chrX and calculated the mean TPM according to
age groups, ignoring sex and tissue origin: 1) Pre-natal; 2) Post-natal; 2a) Post-natal 1: after
birth until four years-old (inclusive). 2b) Postnatal 2: older than four years old.

557

For the neural network, the expression data was stratified by sex: 1) we calculated the mean and variance expression of each gene for females and males independently, for brain, cerebellar tissues and nerve, aggregating in one metavalue the data for the two cerebellar tissues and in another the data for the other brain regions; 2) tau values were also calculated independently for females and males; 3) Brainspan mean and variance TPM for each age group was calculated separately for females and males.

# 564 Canonical transcript selection

565 The criteria for canonical transcript selection prioritized: i) MANE (Matched Annotation be-

566 tween NCBI and EBI) Select transcripts, which were independently identified by both En-

567 sembl and NCBI as the most biologically relevant; and ii) APPRIS-annotated transcripts <sup>56</sup>.

568 TSS, MANE, and APPRIS annotations of transcripts were retrieved from Ensembl Genes 102

569 via BioMart <sup>57</sup>. For most genes (ca. 80%), the canonical transcripts belong to the MANE Se-

- 570 lect category. The longest transcript with APPRIS annotation was selected for ca. 20% of
- 571 genes. In one case, the only existing transcript was kept.

#### 572 **Promoter CpG density**

573 CpG density was calculated for the 4kb region surrounding the transcription start site 574 (TSS $\pm$ 2kb) of the canonical transcripts of chrX protein-coding genes following previous pub-575 lications.<sup>22,58</sup> Promoter sequences were downloaded through UCSC Table Browser.<sup>59</sup> The 576 CpG density, defined as the observed-to-expected CpG ratio, was calculated as follows: num-577 ber of CpG dinucleotides / (number of C x number of G)) × N, where N is the total number of 578 nucleotides in the sequence being analyzed.

#### 579 Exon and promoter conservation across species

580 Nucleotide conservation across 100 vertebrate species was calculated using the phastCons 581 score obtained with the phastCons100way.UCSC.hg38 R package,<sup>60</sup> and represents the prob-582 ability that a given nucleotide is conserved (range 0 to 1). Exon-conservation score was cal-583 culated for each gene on chrX as the average phastCons of all nucleotides belonging to the 584 gene coding sequence. Coding coordinates for the canonical transcripts were retrieved from Ensembl Genes 102<sup>57</sup> using biomaRt R package.<sup>61,62</sup> Promoter-conservation score for each 585 586 gene on chrX was calculated as the average phastCons score of all nucleotides 4kb around the 587 TSS of the canonical transcript.

#### 588 Distance to centromere and telomeres

589 The coordinates from centromeres and telomeres were downloaded through UCSC Table

- 590 Browser. We calculated the distance from the TSS of the canonical transcripts to the centro-
- 591 mere and to the telomere in the corresponding chromosomal arm.

#### 592 Annotation of encoded proteins

593 Data referring to function, subcellular location, subunit structure, and gene ontology terms for

<sup>63</sup> chrX encoded proteins were retrieved from Uniprot.<sup>63</sup>

#### 595 **Paralogues**

All paralogues from chrX genes were retrieve from Ensembl Genes 102 <sup>57</sup> using biomaRt R package.<sup>61,62</sup> The 90<sup>th</sup>, 95<sup>th</sup>, 98<sup>th</sup> and 99<sup>th</sup> and 100<sup>th</sup> percentiles were calculated for i) the percentage of paralogous sequence matching the query sequence and ii) the percentage of query sequence matching the paralogue sequence. Only paralogues with both metrics above the 95<sup>th</sup> percentile were considered as close paralogues.

#### 601 X-chromosome inactivation

602 The information on genes escaping X-chromosome inactivation (XCI) was obtained from multiple publications.<sup>4,64-69</sup> After converting gene identifiers from all studies into HGNC ap-603 604 proved symbols, genes were divided into seven categories based on the agreement between 605 the various studies: 1) high confidence escapee and 2) high confidence non-escapee, when al-606 most all studies agreed on one status; 3) low confidence escapee and 4) low confidence non-607 escapee, whenever some studies disagreed but a higher number of studies reported one status; 608 5) variable escapee, when most studies stated variable escape; 6) discordant, when similar 609 number of studies agreed on both status; 7) not available, when there was not enough data to 610 have reliable evidence of XCI status.

#### 611 Features shared by disorder-causing genes

To uncover no-disorder genes exhibiting similar characteristics to known disorder-causing genes, we considered metrics showing enrichment of confirmed-disorder genes at one of the extremes of the distribution with marked difference between confirmed-disorder and no-disorder genes. Then, we applied a threshold approach to categorize genes showing values within the deciles enriched for confirmed disorder-causing genes for each of the considered

- 617 metrics. The minimum number of criteria showing enrichment for confirmed disorder-caus-
- 618 ing genes was used as the minimum number of criteria required to consider a PMT or no-dis-
- 619 order gene as having similar features to disorder-causing genes.

#### 620 Pre-classification of genes for the neural network

- 621 Genes were pre-classified based on 1) the type of associations with disorders and/or traits
- (confirmed, PMT, no-disorder), 2) the association with a brain disorder and 3) the tolerance 622
- 623 to loss-of-function (LoF) variants (Extended Data Fig. 5). The list of confidently LoF-tolerant
- 624 genes based on the gnomAD dataset was retrieved from data files from Karczewski et al.
- (2020) and consists of genes with at least one homozygous LoF variants.<sup>16</sup> Genes showing no 625
- 626 homozygous LoF variants were considered LoF-intolerant.

#### 627 **Neural Network**

630

628 Information regarding the data fed into the neural network is in Supplementary Tables 7 and 629 8. We used a simple multilayer perceptron (MLP) network with 3 inner layers of size 128

nodes, 64 nodes and 32 nodes with rectified linear unit (ReLU) activation function and a sin-

631 gle output node with sigmoid activation. The weights were initialized with a random normal

- 632 distribution with a bias of zero, and batch normalization and a dropout of 0.5 were applied
- 633 between all layers. Training was performed with a batch size of 5 and data shuffling between
- 634 epochs using stochastic gradient descent (SGD) with a learning rate of 1e-3, no decay, and a
- 635 binary crossentropy / log loss as the objective function.

- 637 tended Data Fig. 5; Supplementary Table 8). Beforehand columns of the training data were
- 638 separately normalized to [0,1] via min-max-scaling.
- To validate the model we performed a 10-fold cross validation by scikit-learn K-Fold <sup>70</sup>, 639

<sup>636</sup> Class labels for the training data T are "Cbi" (C1, value 1.0) and "NDt" (C0, value 0.0) (Ex-

640	which randomly splits T into ten non overlapping parts $T_0$ to $T_9$ each containing 10% of the
641	data (Extended Data Fig. 4). Ten networks are trained. Each network $N_i$ is trained on the nine
642	parts $\{P_j   j \neq i\}$ . Afterwards $N_i$ is applied to the remaining unseen part $P_i$ to create estimation
643	$E_i$ .

We then concatenate all partial estimations to get full estimation  $\cup_i E_i = E$  for each gene in 644 T. Together with the known classes C0 and C1 for each gene, we estimate a threshold t for 645 646 given false discovery rate d. First define functions C1(t) and C0(t) returning all genes of class C1 respectively C0 with estimation score < t. For t > 0.5 we can consider a gene with 647 label T0 to be false positive. Thereby for a given t the empirical FDR can be measured by 648 T1(t)/(T0(t) + T1(t)). By calculating the FDR threshold by estimations on ten different 649 650 neural networks, each applied on unseen data, we ensure that the threshold is not biased by 651 overfitting. FDR thresholds were calculated as 0.8152034 (FDR 0.05) and 0.9745963 (FDR<0.01). 652

Finally, a full network *N* is trained on the full data *T* and applied on the complete data set
with scaled column by the former min-max-scaling. The inferred score for each gene, represents the estimated probability for an association between the gene and a brain diseases.

All computational operations were performed in python with sklearn<sup>70</sup> for normalization and
keras for building and training the neural network.<sup>71</sup> Seeds for numpy, K-Fold and Tensorflow were set to 1094795585.

659

# 660 Known mutations

The number of indels, nonsense, splice site and missense variants reported in PMT and nodisorder genes were retrieved from the Human Gene Mutation Database (HGMD) Professional 2020.3 (Qiagen) and DECIPHER,<sup>72</sup> and normalized by the CDS length. DECIPHER

variants include DDD variants and patient sequence variants that are not benign or likely be-

665 nign.

#### 666 Developmental disorders gene databases

- 667 chrX genes were annotated for their classification in SysID
- 668 (https://www.sysid.dbmr.unibe.ch/)<sup>73</sup> and Gene2Phenotype (https://www.ebi.ac.uk/gene2phe-
- 669 notype)<sup>74</sup> developmental disorders databases, which list genes associated with intellectual
- 670 disability or developmental disorders.

#### 671 Identification of damaging variants in predicted gene

672 *De novo* variants in predicted genes were retrieved from Kaplanis et al.<sup>38</sup> and Martin et al.<sup>21</sup>

673 In addition, we examined variants in predicted genes identified in unsolved cases with

674 developmental disorders from two different cohorts: a cohort from Hôpital Pitié-Salpêtrière

675 (APHP, Paris, France), which mainly includes patients with intellectual disability or

676 neurological disorders (6500 individuals from 2346 families) and a cohort of patients with

677 dysgenesis of the corpus callosum, associated with learning or intellectual disabilities from

678 University of California San Francisco (UCSF; 1399 individuals from 463 families).

- 679 Informed consent of the legal representatives and appropriate approval of an ethics
- 680 committee, according to the French and American laws, have been obtained. Variant data and
- 681 clinical information were shared anonymously. Only damaging variants (*i.e.* variants leading
- to a premature termination codon or missense variants with CADD PHRED scores  $\geq$  25) in
- 683 NN-predicted genes meeting at least one LME criterion were kept for further analysis.

#### 684 Functional validation of *TRPC5* missense variant

685 HEK293 cells were transiently transfected with a plasmid expressing TRPC5-GFP WT or 686 p.Arg175Cys mutant channels. Currents were recorded from green fluorescent cells using the 687 whole-cell configuration of the patch-clamp technique 16 to 24 h after transfection at room 688 temperature. Voltage-clamp recordings were performed using an Axopatch 200B amplifier 689 and a Digidata 1440 Analogue/Digital interface (Axon Instruments). Data were low-pass fil-690 tered at 2 kHz, digitized at 10 kHz and analysed offline using Clampfit software. Currents 691 were recorded during a 500 ms voltage ramp from -100 mV to 100 mV applied from a hold-692 ing potential of -100 mV every 5 s. Series resistance was not compensated, and no leak sub-693 traction was performed. Data were not corrected offline for voltage error and liquid junction 694 potential. The pipette solution contained (in mM): NaCl 8, Cs-methanesulfonate 120, MgCl2 695 1, CaCl2 3.1, EGTA 10, HEPES 10, pH adjusted to 7.3 with CsOH. The extracellular solu-696 tion contained (in mM): NaCl 140, MgCl2 1, CaCl2 2, HEPES 10, glucose 10, pH adjusted to 697 7.2 with NaOH. Immediate currents were recorded upon break-in (using patch pipettes that 698 contained 100 nM free Ca2+). The mutant currents are readily distinguished even in the ab-699 sence of agonist stimulation, indeed the current-voltage relationship (IV) was similar to that 700 described in the literature, showing inward and outward ('double') rectification, giving some-701 thing that is roughly 'Nshaped'. Englerin A (100nM) was applied to the cell expressing WT 702 and mutant TRPC5 without immediate current upon break-in to confirm its functional expres-703 sion.

#### 704 Statistics

Fisher's tests were performed for each chromosome to determine associations between: i)
genes being present in the specific chromosome and genes having an associated phenotype
with Clinical Synopsis data (CS-genes); ii) CS-genes being in the specific chromosome and

708	CS-genes having non-specific or specific neurologic features described in the Clinical Synop-						
709	sis data. For chrX, Fisher's tests were performed to compute the enrichment/depletion of con-						
710	firmed disorder-associated genes in each decile of the distribution of continuous variables.						
711	Odds ratios were log2 transformed and indicate enrichment or depletion of genes, for positive						
712	or negative values, respectively $(10^{-4} \text{ was added prior to transformation, whenever necessary})$						
713	to deal with log of 0 issue). P-values were adjusted for multiple comparisons using Bonfer-						
714	roni correction. For gene prediction, Fisher's tests were performed to calculate the association						
715	between genes being confirmed-disorder genes and the number of predictors. Mann-Whitney						
716	U test followed by Bonferroni correction for multiple testing was used to assess the coding-						
717	sequence length difference between groups of genes.						
718							
719	Data availability						
720	All data are available in the main text or supplementary materials. We used data from HGNC						
721	(https://www.genenames.org/), OMIM (https://www.omim.org/), gnomAD v2.1.1						
722	(https://gnomad.broadinstitute.org/), GTEx Portal (https://gtexportal.org/home/), BrainSpan						
723	Atlas of the Developing Human Brain (https://www.brainspan.org/), Ensembl						
724	(https://www.ensembl.org/index.html), UCSC Table Browser (https://genome.ucsc.edu/cgi-						
725	bin/hgTables), Uniprot (https://www.uniprot.org/), Human Gene Mutation Database						
726	(http://www.hgmd.cf.ac.uk/ac/index.php), DECIPHER (https://www.deciphergenomics.org/),						
727	SysID database (https://www.sysid.dbmr.unibe.ch/), Gene2Phenotype						
728	(https://www.ebi.ac.uk/gene2phenotype) and CADD - Combined Annotation Dependent De-						
729	pletion (https://cadd.gs.washington.edu/).						
730							

# 731 Code availability

- 732 The following publicly available software packages were used to perform analyses: biomaRt
- 733 (https://bioconductor.org/packages/release/bioc/html/biomaRt.html),
- 734 phastCons100way.UCSC.hg38 (http://bioconductor.org/packages/release/data/annota-
- tion/html/phastCons100way.UCSC.hg38.html), rstatix (https://cran.r-project.org/web/pack-
- 736 ages/rstatix/index.html), numpy (https://numpy.org/), scikit-learn K-Fold
- 737 (https://github.com/scikit-learn/scikit-learn) and Tensorflow (https://www.tensorflow.org/).
- 738

#### 739 Supplementary references

- 740 51. Braschi, B. *et al.* Genenames.org: the HGNC and VGNC resources in 2019. *Nucleic Acids Res* 47, D786-D792 (2019).
- 52. Consortium, G.T. The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* 369, 1318-1330 (2020).
- Yanai, I. *et al.* Genome-wide midrange transcription profiles reveal expression level
  relationships in human tissue specification. *Bioinformatics* 21, 650-9 (2005).
- 54. Kryuchkova-Mostacci, N. & Robinson-Rechavi, M. A benchmark of gene expression tissue-specificity metrics. *Brief Bioinform* 18, 205-214 (2017).
- 55. Miller, J.A. *et al.* Transcriptional landscape of the prenatal human brain. *Nature* 508, 199-206 (2014).
- 750 56. Rodriguez, J.M. *et al.* APPRIS: annotation of principal and alternative splice
  751 isoforms. *Nucleic Acids Res* 41, D110-7 (2013).
- 752 57. Yates, A.D. *et al.* Ensembl 2020. *Nucleic Acids Res* **48**, D682-D688 (2020).
- 58. Gardiner-Garden, M. & Frommer, M. CpG islands in vertebrate genomes. *J Mol Biol*196, 261-82 (1987).
- 755 59. Karolchik, D. *et al.* The UCSC Table Browser data retrieval tool. *Nucleic Acids Res*756 32, D493-6 (2004).
- Siepel, A. *et al.* Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. *Genome Res* 15, 1034-50 (2005).
- Durinck, S. *et al.* BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. *Bioinformatics* 21, 3439-40 (2005).
- 62. Durinck, S., Spellman, P.T., Birney, E. & Huber, W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat Protoc* 4, 1184-91 (2009).
- 63. UniProt, C. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res* 47, D506-D515 (2019).
- Cotton, A.M. *et al.* Landscape of DNA methylation on the X chromosome reflects
  CpG density, functional chromatin state and X-chromosome inactivation. *Hum Mol Genet* 24, 1528-39 (2015).
- Carrel, L. & Willard, H.F. X-inactivation profile reveals extensive variability in Xlinked gene expression in females. *Nature* 434, 400-4 (2005).

- 771 66. Wainer Katsir, K. & Linial, M. Human genes escaping X-inactivation revealed by single cell expression data. BMC Genomics 20, 201 (2019). 772
- 773 Balaton, B.P., Cotton, A.M. & Brown, C.J. Derivation of consensus inactivation 67. 774 status for X-linked genes from genome-wide studies. *Biol Sex Differ* 6, 35 (2015).
- 775 Zhang, Y. et al. Genes that Escape X-Inactivation in Humans Have High Intraspecific 68. 776 Variability in Expression, Are Associated with Mental Impairment but Are Not Slow 777 Evolving. Mol Biol Evol 33, 302 (2016).
- 778 Oliva, M. et al. The impact of sex on gene expression across human tissues. Science 69. 779 **369**(2020).
- 780 Pedregosa, F. et al. Scikit-learn: Machine learning in Python. Journal of Machine 70. 781 Learning Research, 2825–2830 (2011).
- 782 Chollet, F. Keras: the Python deep learning API. (2005). 71.
- 783 72. Firth, H.V. et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in 784 Humans Using Ensembl Resources. Am J Hum Genet 84, 524-33 (2009).
- 785 73. Kochinke, K. et al. Systematic Phenomics Analysis Deconvolutes Genes Mutated in 786 Intellectual Disability into Biologically Coherent Modules. Am J Hum Genet 98, 149-787 64 (2016).
- 788 74. Thormann, A. et al. Flexible and scalable diagnostic filtering of genomic variants 789 using G2P with Ensembl VEP. Nat Commun 10, 2373 (2019).

# 790 Acknowledgements

The authors thank the patients with *CDK16* and *TRPC5* pathogenic variants and their family

- for their participation in this study. We kindly thank Mrs Céline Cuny for Sanger sequencing
- analysis of the patient with TRPC5 missense variant. Electrophysiological experiments were
- carried out at the electrophysiology core facility of ICM funded from the program "Inves-
- tissements d'avenir" ANR-10-IAIHU-06. We thank Universitätsklinikum Essen, University
- 796 Duisburg-Essen, the Deutsche Forschungsgemeinschaft (DFG), the Tom-Wahlig-Stiftung
- 797 (TWS), the Deutsche Stiftung Neurologie (DSN), and Assistance Publique des Hôpitaux de
- Paris (APHP) for their financial support to the research studies conducted by the authors. E.L.
- and F.K. are associated with the FOR 2488 project (DFG, Project number 287074911). This
- study makes use of data generated by the DECIPHER community. A full list of centres who
- 801 contributed to the generation of the data is available from https://decipherge-
- 802 nomics.org/about/stats and via email from contact@deciphergenomics.org. Funding for the
- 803 DECIPHER project was provided by Wellcome.
- 804

## 805 Author Contributions

- 806 E.L. and C.De. conceived and supervised the study. E.L. and C.S. performed the computa-
- tions. E.L., I.P., C.Da., A.R., T.K., S.K., N.D., and C.E. carried out the experiments. A.K.,
- 808 B.G., E.S., C.N., J.P., B.D-B., L.V., A.P.A.S., E.K.V., J.A.J.V., F.J.K., F.T.M-T., M.S., P.S.,
- 809 S.G.M.F., E.A., E.H.S., F.E., J.B., B.K., C.M., D.H., J-L.M., J.G., V.M.K., B.H., and A.P.
- 810 contributed analysis, data and/or critically revised the manuscript for intellectual content.
- 811 E.L. and C.De. drafted the manuscript. All authors reviewed and approved the manuscript.

812

## 813 Competing Interests statement

814 The authors declare no competing interests.



815 Fig. 1: Disorder genes across chromosomes. a, Number of protein-coding genes on chrX. 816 Genes associated with at least one monogenic disorder: orange, confirmed genes; blue: genes 817 with provisional associations (P), associated with susceptibility factors to multifactorial disor-818 ders (M) or traits (T) (altogether: PMTs); grey: genes without known phenotypes (no-disorder 819 genes). b, Number of protein-coding genes per chromosome. Dark and light colors represent 820 genes with Clinical Synopsis (CS) data for at least one of the associated phenotypes (+CS) or 821 without CS (-CS), respectively. c, *Per* chromosome enrichment/depletion of protein-coding 822 genes with at least one associated phenotype comprising Clinical Synopsis data (confirmed 823 CS-genes). d, Fraction of confirmed CS-genes among protein-coding genes. e-n. Predomi-824 nance of chrX genes associated with neurologic features. e, g, i, k and m, Per chromosome 825 enrichment/depletion of genes with non-specific neurologic features (e), intellectual disability 826 (g), seizures (i), language impairment (k) or motor development (m). f, h, j, l and n, Fraction 827 of genes associated with non-specific neurologic features (f), intellectual disability (h), sei-828 zures (j), language impairment (l) or motor development (n). c-n, Yellow, enrichment; dark-829 grey, depletion; light grey, not significant. Terms corresponding to the same neurological 830 clinical features were used in OMIM searches (Supplementary Table 2). Only significant p-831 values are shown (Fisher's test followed by Bonferroni correction for multiple testing; Sup-832 plementary Tables 4 and 5). o, Scheme of genes associated with neurological features on 833 chrX. Squares next to the genes represent association with intellectual disability (blue), sei-834 zures (green) or language impairment (cyan). A horizontal line separates genes present in dif-835 ferent chromosome bands.



836 Fig. 2: Prediction of disorder-genes. a-c, Density plots showing the distribution of LOEUF 837 (a), misZ (b) and exon-conservation score (c) according to gene group. Confirmed disorder 838 genes (orange), PMT genes (blue), no-disorder genes (grey). Vertical dashed lines separate 839 deciles of the overall distribution. Grey areas depict deciles for which confirmed disorder-as-840 sociated genes are enriched (related to Extended Data Fig. 2). d, Overview of the approaches 841 used to uncover features shared by disorder genes and to predict new putative disorder-genes (details in Supplementary Methods). e, Euler diagrams showing the number of genes ful-842 843 filling LOEUF (L), misZ (M) and exon-conservation (E) criteria for confirmed (left), PMT 844 (middle) and no-disorder genes (right). Thresholds: LOEUF  $\leq 0.326$ , misZ  $\geq 2.16$ , exon-con-845 servation score  $\geq 0.9491$ . Genes fulfilling at least two LME criteria are shown in green (light 846 or dark green for two or three criteria, respectively). Genes meeting only one of the metrics 847 are shown in different shades of grey (dark to light: LOEUF, misZ, exon-conservation). f, Euler diagrams showing the number of genes fulfilling LME criteria (LME, green), predicted by 848 849 the neural network (vellow) or both (blue) for confirmed (left), PMT (middle) and no-disor-850 der genes (right). e and f, Genes neither predicted by the neural network nor meeting LME 851 criteria are shown in white.









\*\* Current primary ID genes / ID data freeze

NN L M E

1 1 1 1



С





\* ID candidate genes



LME only

е



LME=1				
	NN	L	М	Е
ACE2	1	1		
AKAP4	1	1		
AMOT	1	1		
APEX2	1	1		
ARAF	1		1	
ARHGAP4	1	1		
ARHGAP6	1	1		
ARHGEF6*	1	1		
ARMCX3	1			1
ATG4A	1	1		
BEX3	1			1
BRCC3	1		1	
BRS3	1	1		
CENPI	1	1		
CFAP47	1	1		
CHIC1	1			1
CTPS2	1		1	
DOCK11	1		1	
EFHC2	1	1		
ELK1	1		1	
FGF13**	1			1
GABRA3*	1		1	
GNL3L	1	1		
GPKOW	1	1		
GPR173	1		1	
HAUS7	1	1		
HDX	1			1
HTATSF1	1	1		
IDH3G	1		1	
IL13RA1		1		
INTS6L	1	1		
IRAK1	1	1		
JADE3	1	1		
LRCH2	1	1		
MAGEE1	1	1		
MAOB	1	1		
MCF2	1	1		_
MCTS1	1			1
MMGT1*		_		
MORC4				_
MOSPD1		_		
MOSPD2				
MPP1				

LME=2

ATP2B3\*

HDAC6\*

KIF4A\*\*

RBMX\*

NLGN3\*\*

PTCHD1\*\*

NN L M E

	NN	L	м	Е
MTCP1	1			1
MTMR1	1	1		
NRK	1	1		
PCDH11X	1		1	
PDZD11	1			1
PDZD4	1		1	
PIM2	1	1		
PIN4	1			1
PPEF1	1	1		
PRPS2	1		1	
RAB9B	1			1
RAP2C	1			1
RBM41	1	1		
RIBC1	1	1		
RPL36A	1			1
RPL39	1			1
RRAGB	1			1
RTL9	1	1		
SH3BGRL	1			1
SLC25A5	1		1	
SLC7A3	1	1	_	
SLITRK2	1		1	
SNX12	1			1
SPIN4	1			1
STK26	1			1
TAB3	1			1
TAF7L	1	1		
TBC1D25	1		1	
TKTL1	1	1		
TLR8	1		1	
TMEM47	1			1
TMSB4X	1			1
TNMD	1			1
TXLNG	1	1		
UTP14A	1	1		
VAMP7	1			1
WDR13*	1		1	
WWC3	1	1		
ZDHHC15*	1	_		1
ZNF182	1	1		
ZNF280C	1	1		
ZNF449	1	_	1	
ZRSR2	1	1		
ZXDB	1	1		

LME=1

ATP11C

COL4A6

DIAPH2\*

GPRASP2 PDK3

SH3KBP1

NN L M E

1 1

b NN + LME=0



d NN + LME=0



ZBTB33

# 852 Fig. 3: Different evidence strength for the predicted disorder-associated genes. a-d, PMT

- 853 (**a**, **b**) and no-disorder genes (**c**, **d**) predicted by the neural network as possibly disease-associ-
- ated, either fulfilling (**a**, **c**) or not LME criteria (**b**, **d**). Genes present in the SysID database as
- 855 "ID candidate genes" (\*) and "Current primary ID" or "ID data freeze" (\*\*) are marked. e,
- 856 No-disorder genes meeting LME criteria but not predicted by the neural network.



#### 857 Fig. 4: External supporting evidence for the predicted disorder-associated genes. a and

- b, Known point mutations in no-disorder genes. Boxplot showing the number of known mu-
- tations reported in HGMD and DECIPHER (a) or their value normalized by coding-sequence
- 860 (CDS) length (b) according to their predicted status. No-disorder genes meeting LME criteria
- but not predicted by the neural network were omitted from the analysis. Box plot elements
- 862 are defined as follows: center line: median; box limits: upper and lower quartiles; whiskers:
- 863 1.5× interquartile range; points: outliers. Related to Supplementary Table 9. c, Number of no-
- disorder genes present in the SysID database according to their predicted status.



### 865 Fig. 5: Damaging variants in selected predicted disorder-associated genes. Schematic

- 866 representation of the coding exons, protein domains (when present) and available damaging
- 867 variants (truncating or CADD≥25) for each selected predicted gene. Types of variants are
- 868 shown in different colors: lof-of-function (LoF, red), missense (blue), splicing (orange). Pro-
- tein functional domains are shown: domains (light red), transmembrane segments (purple),
- 870 NHL, YD or WD40 repeats (light blue), coiled-coils (yellow), zinc-fingers (green). HGVS
- 871 cDNA and HGVS protein descriptions are shown. The corresponding RefSeq identifier of the
- 872 MANE Select transcript and Uniprot identifier are shown for each gene. Details of variants
- displayed in this figure appear in Supplementary Table 11.



а

#### Fig. 6: Validation of selected predicted disorder-associated genes: CDK16 and TRPC5. a

and b, Schematic representation of the coding exons, protein domains and variants of *CDK16* 

- 876 (a) and *TRPC5* (b). Variant types: loss-of-function (LoF, red), missense (blue). c, Pedigrees
- 877 of the three families with *CDK16* variants. The pedigree of family with c.976\_977del,
- 878 p.(Trp326Valfs\*5) was adapted from Hu et al. (2016)<sup>18</sup>. The two remaining families are un-
- published. d, Pedigrees of the three families with TRPC5 variants. The family with an intra-
- genic exon deletion was reported in Mignon-Ravix et al.  $(2014)^{43}$ . The two other families are
- 881 novel. e-g, Functional characterization of TRPC5 p.R175C by whole-cell patch-clamp record-
- ings showing that the mutation renders the mutant channel constitutively opened. e, Time
- 883 course of inward and outward current amplitudes measured at +80 mV and -80 mV in
- HEK293 cells transiently expressing WT (black) and mutant TRPC5 (red) in presence of
- 100nM free Ca<sup>2+</sup> in the pipette. Values are reported as mean  $\pm$  SEM. Recordings started few
- seconds after the rupture. **f**, Representative whole-cell current-voltage (I-V) relationships of
- WT and mutant TRPC5 channels current obtained shortly after break-in ( $\leq 10$  s) with 100nM
- free  $Ca^{2+}$  in the pipette. **g**, Boxplot of WT and mutant whole-cell current at -80 mV and +80
- 889 mV after break-in (one-way ANOVA with Dunnett's post hoc test). The number of independ-
- 890 ent recordings appears in brackets. Details of variants displayed in this figure appear in Sup-
- 891 plementary Table 12.